Page 11234..1020..»

Archive for the ‘Stem Cell Therapy’ Category

Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients – ScienceAlert

Wednesday, March 3rd, 2021

Spinal cord injuries are sustained by hundreds of thousands of people every year, with many patients experiencing a significant and often permanent loss of movement and physical sensation resulting from nerve damage.

Beyond intensive physical rehabilitation programs which can improve outcomes in some cases treatment options are virtually non-existent. But new results from a phase 2 clinical trial offer fresh hope for remedies on the horizon.

In an experimental collaboration by scientists in Japan and the US, 13 patients with spinal cord injuries (SCI)experienced a range of functional improvements in their condition after being treated with an intravenous infusion of their own stem cells, derived from their bone marrow.

The stem cells in question are known as mesenchymal stem cells (MSCs), which are multipotent adult stem cells with the ability to differentiate into a variety of cell types, enabling them to repair bone, cartilage, muscle, or fat tissue.

Despite the potential promise of these cells, their use as an actual therapy has generated considerable controversy, especially after Japan fast-tracked commercialisation approval in late 2018in advance of thorough data on the safety and effectiveness of the experimental treatment.

Over two years later, the researchers behind the therapy, called Stemirac, now have more of those data to share, and while it won't be enough to placate critics, the findings nonetheless offer valuable new information on what MSCs may do for patients with SCI.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study .

"Now we have a hint, in humans, that it may be possible."

In the study, the researchers point out that while other trials have also looked at using MSCs to treat SCI via injection methods, their own technique, using intravenous infusion, could have particular benefits.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

Whether that explains some of the results seen in their 13 patients is unclear, but the outcomes themselves are notable.

Of the individuals treated with Stemirac, all of whom had non-penetrative SCIs (meaning their spinal cords were not severed) sustained during serious physical accidents, all but one had demonstrated improvements in key sensory or motor functions by six months after the infusion.

Over half the group showed substantial improvements in things like walking ability or using their hands, and in many cases, graded improvements on a standardised impairment scale could be seen as soon as one day after the treatment, although other cases took weeks.

Significantly, no adverse effects were reported.

While the researchers acknowledge that theirs is a small trial with various limitations including the possibility that the recoveries seen may have been somewhat spontaneous they contend that the initial data show we're looking at something here that's safe, feasible, and worthy of follow-up studies with greater amounts of patients.

"Although this initial case study was unblinded and uncontrolled, the SCI patients appeared to demonstrate a tendency of relatively rapid improvement of neurological function that was often apparent within a few days following infusion of MSCs," the team writes.

As for how the MSC infusion delivers its healing, results from studies on animals have made the researchers think the stem cells secrete neural growth factors that restore important structures that reduce swelling, while restoring vital chemical activity.

In terms of the rapid improvements, the team suggests a chemical called brain derived neurotrophic factor (BDNF) may be involved, which is known to support the health of neurons via numerous mechanisms.

Hopefully, more research in the future can demonstrate the true extent of the potential benefits of this treatment.

The findings are reported in Journal of Clinical Neurology and Neurosurgery.

Visit link:
Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients - ScienceAlert

Read More...

Cynata tests wound dressing tech for stem cell therapy delivery – The West Australian

Wednesday, March 3rd, 2021

ASX-listed Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCytes proprietary surface modifications of polymer-coated dressings for the delivery of Cynatas mesenchymal stem cells, or MSC, to wounds.

The Melbourne-based clinical-stage stem cell and regenerative medicine company is specifically looking to use TekCytes technologies in the commercial development of Cynatas MSC product for the treatment of diabetic foot ulcers.

Cynata said its trademarked Cymerus MSCs have already demonstrated promising efficacy in a pre-clinical model of diabetic wounds, often referred to as diabetic ulcers, utilising TekCytes dressing when seeded with MSCs or similar cells.

The company now plans to build on the solid pre-clinical foundation by conducting a clinical trial of its Cymerus MSC product on patients with diabetic foot ulcers using an active dressing supplied by TekCyte.

Cynata expects to start the clinical trial as soon as possible after it completes negotiations with TekCyte on a formal license agreement.

The company says diabetic foot ulcers are a significant medical problem with an estimated market value of nearly US$10 billion based on data sourced from Transparent Market Researchs review of the global diabetic foot ulcers treatment market out to 2027.

In Australia alone, diabetic foot disease results in more than 27,000 hospitalisations, 4,400 amputations and 1,700 deaths annually. Unfortunately, there is also evidence that the burden of this disease is growing year-on-year, and existing treatment options have limited success.

The very encouraging data from the pre-clinical studies at the CTM-CRC with our Cymerus MSC product, especially when compared with other cell products, provides a rational and sound basis for us to proceed with TekCytes patch technology.

Elsewhere in Cynatas labs and clinical trial sites, the company is working to deploy its stem cell technology across a range of ailments, including Osteoarthritis, renal transplantation, idiopathic pulmonary fibrosis and even COVID-19.

Stem cells, most familiar as embryonic stem cells, are special human cells capable of morphing into all other cell varieties from muscles to brain cells.

Whilst stem cell technology has been developing for a decade or two now, it has been routinely based on using hematopoietic stem cells to treat disease. However, a donor can currently transplant these cells only if a perfect match is available.

Instead of the arduous process of undertaking donor match searches, Cynata believes plentiful stem cells can be derived another way. By transforming adult stem cells with a type of genetic reprogramming, the company says it can create pluripotent stem cells that are capable of operating identically to the valuable embryonic cells.

The companys proprietary Cymerus technology uses pluripotent cells combined with a precursor cell called mesenchymoangioblasts, or MCA to fabricate numerous cell therapy products, including mesenchymal stem cells or MSCs.

Importantly, Cynata says it can produce those essential cells at a commercial scale, forgoing the need for multiple donors and conquering the usual supply bottlenecks currently frustrating stem cell therapies and researchers worldwide.

Other candidate diseases facing this potentially boundless technology include asthma, heart attack, sepsis, acute respiratory distress syndrome, or ARDS and cytokine release syndrome.

Plans are already well advanced for further clinical trials of the fascinating Cymerus MSC products in Graft-versus-host Disease, or GvHD through licensee Fujifilm.

GvHD is an all-too-common consequence of traditional stem cell therapies and is one of the earliest ailments to be attacked by Cynatas technology.

Cynata looks to be hurtling down a path to turn science fiction into reality by developing a wound patch that can effectively regenerate the bodys own cells a bit more than just a band-aid approach, perhaps?

Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au

Original post:
Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian

Read More...

Stem Cell Injections Could Treat Spinal Cord Injuries | IE – Interesting Engineering

Wednesday, March 3rd, 2021

Injecting bone marrow stem cells in patients with spinal cord injuries significantly improved their motor functions.

Scientists from Yale University and Sapporo Medical University in Japan reported their findings in the Journal of Clinical Neurology and Neurosurgery on February 18.

The stem cells were prepared from the patients' own bone marrow, and injected intravenously back into the patients, with no side effects from the therapy noted by the researchers. This was not a blind trial, and no placebos were administered.

Over half of the patients reported improved motor functions within weeks of the injections. Key motor functions include walking and using hands.

The patients in question had experienced non-penetrating spinal cord injuries a few weeks prior to the study, which were caused by minor falls or trauma. These injuries left them without motor function or coordination, sensory loss, and bowel and bladder dysfunction.

This type of therapy isn't only ideal for spinal cord injuries, but also for brain injuries, such as strokes. As Jeffery Kocsis of Yale University said "Similar results with stem cells in patients with stroke increases our confidence that this approach may be clinically useful."

Adding to this comment, Stephen Waxman from Yale University said "The idea that we may be able to restore function after injury to the brain and spinal cord using the patients own stem cells has intrigued us for years. Now we have a hint, in humans, that it may be possible."

It's still the early days of this stem cell therapy for spinal cord injuries, and the authors of the study stress that further studies need to be carried out before confirming the results of their initial, unblinded trial something that could take years.

It's still exciting news, as stem cell therapy has been researched for years as a potential remedy for such injuries. Just last year, the Mayo Clinic carried out trials on stem cell therapy for spinal cord injuries. While in Japan, a few eyebrows were raised in 2019 as the nation accepted stem cell therapy to treat spinal cord injuries, perhaps a little prematurely some scientists suggested in the journal Nature.

Continue reading here:
Stem Cell Injections Could Treat Spinal Cord Injuries | IE - Interesting Engineering

Read More...

NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T – PharmiWeb.com

Wednesday, March 3rd, 2021

Theglobal Canine Arthritis Treatment Marketis expected to reachUS$ 3051.8 Mnby 2028, growing at a moderate CAGR of 4.4%, as per a market intelligence outlook by Future Market Insights, a premier market research firm delivering actionable insights to key leaders across the globe. Mostly found in ageing canines, canine arthritis is a degenerative condition that results in joints inflammation and progresses with time if left untreated. The condition further worsens resulting in associated conditions like osteoarthritis, osteophytosis, and loss of cartilage, in response to pain and inflammation. Injuries, obesity, and poor bone development often leads to canine arthritis.

Rising number of chronic diseases in dogs, globally, is the primary factor driving canine arthritis treatment adoption. Additional factors like increasing number of veterinary clinics couple with stem cell transplants and Non-steroidal anti-inflammatory medications (NSAIDs) are likely to push the market for canine arthritis treatment. Non-steroidal anti-inflammatory medications (NSAIDs) segment is expected to made substantial revenue contribution to overall canine arthritis treatment market followed by opioids during forecast period.

North America, followed byEuropeandAsia Pacific, is expected to be largest consumer of canine arthritis treatment drugs and therapies, owing to existence of developed regulations and superior healthcare infrastructure. For more collaborative research in the canine arthritis market,JapanandSpainare projected to be promising markets.

A sample of this report is available upon request @https://www.futuremarketinsights.com/reports/sample/rep-gb-3552

Use of NSAIDs to Further Shape Canine Arthritis Market

Ease of FDA approval for novel and innovative canine arthritis treatment drugs coupled with growing adoption of canine stem therapy to treat arthritis and huge investments in research and development for the production of NSAIDs and opioids indicated for arthritis especially in European countries is projected to projected to present opportunities to canine arthritis treatment product manufacturers.

The focus presently is on developing high grade NSAIDs, as these drugs are frequently used to manage canines condition-offering a dramatic improvement in mobility and quality of life. The demand for NSAIDs in on a perpetual rise as it lowers the production of prostaglandins-associated with driving inflammation leading to arthritis. In terms of treatment, NSAIDs are continue to be the globally accepted mainstay of pharmaceutical treatment for canine arthritis, further shaping the canine arthritis treatment market. Research suggests that more than 60% of canines above the age of 7, suffer from degenerative joint diseases.

According to a Healthcare Expert at Future Market Insights, Factors such as growing prevalence of chronic diseases in dogs, rising pets adoption, increased consumer spending on veterinary care and fast FDA approvals for drugs used for canine arthritis treatments are expected to boost the global canine arthritis treatment market during the forecast period. Additionally, canine owners opting for canine stem cell therapy over drug medicines is the most lucrative segment in terms of investment opportunities. However, safety issues affecting clinical efficacy of canine pluripotent cells and high therapy costs limit the adoption of canine stem cell therapy. FDA-approved MediVets Autologous Stem Cell and Aratanas Galliprant to control pain and inflammation associated with arthritis, are expected to contribute to the growth of the canine arthritis treatment market.

However, illicit drugs that are falsely registered could restrain the canine treatment market. Such drugs are not manufactured in accordance with regulations, inversely affecting the dogs health coupled with sales of approved drugs. Research shows that counterfeit medicines are more prevalent in under-developed and developing countries. Growing international trade and ecommerce penetrations are fuelling the sales of sub-standard medicine.

Get Access to Research Methodology Prepared by Experts>>>https://www.futuremarketinsights.com/ask-question/rep-gb-3552

Canine Insurances & Direct Drug Sales to Open Canine Arthritis Treatment Opportunities

Pet insurance is an upcoming trend, especially in mature economies. With only 1% dogs insured in the US, the trend is catching up in the region, opening up opportunities for veterinary insurance vendors. However, this number is as high as 50% for pet dogs in some European countries. Moreover, introduction of third-party payers is expected to boost the turnover of the canine arthritis drugs, mostly for the NSAIDs and stem cell therapy segments globally, and lead to build-up of new sales channels for drugs treating canine arthritis.

Also, canine healthcare products manufacturers are relying on direct sales to end-users in a bid to reach out to a larger consumer base. Furthermore, by adopting this sales route, companies are also providing additional training and support in terms of disease management and adherence to treatment protocols.

Key players including Boehringer Ingelheim, Elanco (Eli Lilly and Company), Zoetis Inc., Bayer AG, Aratana Therapeutics Inc., Vetoquinol S.A., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc are developing cost-effective drugs for canine arthritis treatment and increasing sales through acquisitions to enhance their respective market share. Manufacturers are also focusing in developing novel stem cell therapies for treating arthritis. Moreover, companies are focusing partnering with wholesalers, distributors and other channel partners to gain ownership over value chain.

Preview Analysis OnCanine Arthritis Treatment Market Segmentation By treatment type Non-steroidal anti-inflammatory drugs, Opioids, Stem Cell Therapy; route of administration Oral, Injectable:https://www.futuremarketinsights.com/reports/canine-arthritis-market

More from Healthcare, Pharmaceuticals and Medical devices:

Original post:
NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com

Read More...

Overview of stem cells therapy in amyotrophic lateral sclerosis – DocWire News

Wednesday, March 3rd, 2021

This article was originally published here

Neurol Res. 2021 Feb 25:1-17. doi: 10.1080/01616412.2021.1893564. Online ahead of print.

ABSTRACT

Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons with high burden on society. Despite tremendous efforts over the last several decades, there is still no definite cure for ALS. Up to now, only two disease-modifying agents, riluzole and edaravone, are approved by U.S. Food and Drug Administration (FDA) for ALS treatment, which only modestly improves survival and disease progression. Major challenging issues to find an effective therapy are heterogeneity in the pathogenesis and genetic variability of ALS. As such, stem cell therapy has been recently a focus of both preclinical and clinical investigations of ALS. This is because stem cells have multifaceted features that can potentially target multiple pathogenic mechanisms in ALS even though its underlying mechanisms are not completely elucidated. Methods & Results: Here, we will have an overview of stem cell therapy in ALS, including their therapeutic mechanisms, the results of recent clinical trials as well as ongoing clinical trials. In addition, we will further discuss complications and limitations of stem cell therapy in ALS. Conclusion: The determination of whether stem cells offer a viable treatment strategy for ALS rests on well-designed and appropriately powered future clinical trials. Randomized, double-blinded, and sham-controlled studies would be valuable.

PMID:33632084 | DOI:10.1080/01616412.2021.1893564

Read the original:
Overview of stem cells therapy in amyotrophic lateral sclerosis - DocWire News

Read More...

We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients – RT

Wednesday, March 3rd, 2021

Using a somewhat controversial stem cell therapy, a joint team of Japanese and US-based researchers have successfully repaired some damage in 13 patients with spinal cord injuries (SCI).

SCIs can often cause permanent loss of movement and physical sensation from resultant nerve damage. While physical rehabilitation programs can partially improve outcomes, actual treatment and recovery of lost mobility and function is nigh on impossible. Until now, perhaps.

According to new results from a phase 2 clinical trial conducted in an experimental collaboration by scientists in Japan and the US, patients treated with an intravenous infusion of their own mesenchymal stem cells (MSCs), harvested from their bone marrow, saw significant functional improvements.

MSCs are adult stem cells with the uncanny ability to morph into numerous different cell types, affording them the ability to repair different tissues in the human body, ranging from bone and cartilage to muscle or other tissues.

In 2018, Japan fast-tracked commercial approval of the treatment, opting to forego full testing and regulatory approval despite a lack of complete data on its safety and efficacy. This was much to the consternation of the medical industry at large, and caused considerable controversy in the process.

Fast-forward to the present day and the therapy, called Stemirac, may prove revolutionary in treating non-penetrative SCIs, in which the spinal cord is damaged but remains intact.

In the trials, all 13 patients demonstrated improvements in sensory and motor function six months after they received their infusion, while more than 50 percent of the participants saw substantial improvements in motor function, including walking within a day, though for others it took weeks.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study.

"Now we have a hint, in humans, that it may be possible."

Other research has examined the efficacy of injected MSCs to treat SCI, but this new method involves intravenous infusion, which operates in a different way and, so far, has no adverse effects. Still, the researchers acknowledge the limited scope of the trial, as well as the fact that it was unblinded and uncontrolled.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

For now, they suspect the stem cells secrete neural growth factors, particularly brain-derived neurotrophic factor (BDNF), which have a restorative as well as anti-inflammatory effect. While a lot more research is needed to determine the long term safety and efficacy of the treatment, it could one day prove revolutionary.

Think your friends would be interested? Share this story!

More:
We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT

Read More...

Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -…

Wednesday, March 3rd, 2021

Global Stem Cell Therapy Market 2021 Research Report Including Pre COVID-19 and Post COVID-19 Market Scenario

The recent corona crisis (COVID-19) has disrupted national and international Stem Cell Therapy business, adversely affecting the current and future activities of the Stem Cell Therapy industry. It will have a direct and indirect impact on Stem Cell Therapy industry stakeholders and its integrated industries. The significant impact from the COVID-19 lockdown will be on Stem Cell Therapy consumption. Given the current market conditions, the virus is rapidly changing the consumption and supply chain of companies in the market.Global marketers have observed in the latest market intelligence survey that the global Stem Cell Therapy market will record a value of about US $ xx Mn in 2019 and will grow at a CAGR of xx% during the estimated period 2020-2027. In terms of product type, the segment has a significant share of end applications. All Stem Cell Therapy consumption trends and recruitment patterns are listed in the report.

GetFree Sample [emailprotected]https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027#request-sample

Global Stem Cell Therapy Market Key Players:

Segments of the Stem Cell Therapy Report:

Market Segment By Type:

Market Segment By Application

Stem Cell Therapy Market analysis report helps you with intelligent decision-making and better manages the marketing of goods and services leading to business growth. The Stem Cell Therapy Market report looks at the market in terms of general market conditions, industry improvement, market scenario, development, cost and profit in specific market regions, position among key players, and comparative prices. The data and information contained in this Stem Cell Therapy Market business report not only helps businesses make data-driven decisions but also ensures maximum return on investment (ROI).

Do Inquiry Before Purchasing Report Here and Ask For Discount https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027#inquiry-before-buying

The Stem Cell Therapy Industry Report provides in-depth analysis and insights into the developments impacting business and enterprises at the global and regional level. This research report presents a detailed analysis of the key trends, drivers, constraints, and opportunities influencing sales growth. This study focuses on the global Stem Cell Therapy market by share, volume, value, and shape by region along with type and application.

The geographical analysis covers the following regions: North America Europe Asia Pacific Latin America Middle East and Africa

Stem Cell Therapy Market Research provides the following information In-depth analysis of drivers, constraints, opportunities, and trends influencing the growth of the global Stem Cell Therapy market. Important analysis of the Stem Cell Therapy market by product type and end-use industry. Thorough understanding of the strengths, weaknesses, opportunities, and threats of various Stem Cell Therapy market players. Accurate year-on-year growth of the global Stem Cell Therapy market in terms of value and size.

Key questions answered in this report are: What was the global market size in 2019? What is the market size of the different regions and countries around the world? What factors contribute to the development and what are the constraints on development? What types of applications and products are covered in this report? How can market forecasting statistics help the industry growth? What are the potential investment possibilities of the market in other countries/regions?

Browse Detailed Description, TOC, Detailed Segment analysis, Table Of Figures, https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#table-of-contents

https://neighborwebsj.com/

Originally posted here:
Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -...

Read More...

Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU…

Wednesday, March 3rd, 2021

MarketQuest.biz has presented updated research report titled Global Animal Stem Cell Therapy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 which presents vital answers and interpretations concerning market growth and developments in the market. The report contains insightful information like market share, market size, and growth rate, as well as several challenges and ingrained threats and limitations that have interrupted normal growth prognosis in global Animal Stem Cell Therapy market. The report analyzes the segment expected to dominate the industry and market.This market report includes quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. The report gives information about the supply and demand situation, the competitive scenario, market opportunities, and the threats faced by key players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Intelligence:

The leading players are covered in the global Animal Stem Cell Therapy market report with product description, business outline, as well as production, future demand, company profile, product portfolio, product/service price, capacity, sales, and cost. So the entire information related to the company concerning the specific product and in-depth information of collaborations and all other essential information is added in the research report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/13731

Report has been segmented into geographical segmentation, key players, key topics industry value and demand analysis and forecast and gives comprehensive investigation.The report provides knowledge of the key product segments and their future by having complete insights of market and by making in-depth analysis of market segments. Report includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of global Animal Stem Cell Therapy market.

All top players actively involved in this industry are as follows: Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel

The report highlights product types which are as follows:Dogs, Horses, Others

The report highlights top applications which are as follows:Veterinary Hospitals, Research Organizations

Promising regions & countries mentioned in the global Animal Stem Cell Therapy market report:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market By Manufacturing Cost Analysis:

The study report includes key raw materials analysis, the price trend of key raw materials, key suppliers of raw materials, market concentration rate of raw materials, the proportion of manufacturing cost structure, and manufacturing process analysis. Moreover, the report evaluates the product pricing, production capacity, demand, supply, as well as the historical performance of the global Animal Stem Cell Therapy market.

ACCESS FULL REPORT: https://www.marketquest.biz/report/13731/global-animal-stem-cell-therapy-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Report Offerings:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketquest.biz

Read the original post:
Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU...

Read More...

Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network – The…

Wednesday, March 3rd, 2021

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Animal Stem Cell Therapy Market report provides in-depth knowledge and insights into the Animal Stem Cell Therapy market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Animal Stem Cell Therapy market that has been further validated and verified by industry experts and professionals. The Animal Stem Cell Therapy market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Animal Stem Cell Therapy market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Animal Stem Cell Therapy industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Animal Stem Cell Therapy Market:

Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Segmentation of Animal Stem Cell Therapy Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Dogs Horses Others

By the application, this report covers the following segments:

Veterinary Hospitals Research Organizations

Animal Stem Cell Therapy Market Report Scope

Animal Stem Cell Therapy Geographic Market Analysis:

The latest business intelligence report analyzes the Animal Stem Cell Therapy market in terms of market reach and customer base in key geographic market regions. The Animal Stem Cell Therapy market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Animal Stem Cell Therapy market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Animal Stem Cell TherapyMarket Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Animal Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

Read the rest here:
Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The...

Read More...

Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network – The Bisouv…

Wednesday, March 3rd, 2021

The Stem Cell Therapy Market research report represents a detailed analysis of the future scope, market numbers, revenue, market share, and growth factors for the historic and forecast period 2015-2027. Download a free sample report for a better understanding (Get Free Sample Report)

The Global Stem Cell Therapy Industry Research Report covers 360 degree fundamental market statistics. The competitive structure, market size, market share, revenue analysis and trends are explained in detail in this study. It reflects the product portfolio, specifications, industry plans and policies, and market scope. This is a comprehensive survey that includes a analysis of major player and their market size, share, Business Overview, growth, revenue, compnay profile, Product Profiles, Application and Specification, growth strategies, Market Performance (2015-2020).

This report considers the worlds top players in the industry.

Key PLayers:

This report will help you understand how COVID-19 affected the growth, revenue and more of the Stem Cell Therapy market in 2019-2020 (1st, 2nd, 3rd and 4th quarters). This includes historical and forecast data from 2015 to 2027.

Download Free Sample Including COVID-19 Impact Analysis, TOC, TOF, Charts, Graphs, Detailed Segment Analysis, Key Players Analysis(SWOT & Porters 5 Forces Analysis):https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#request-sample

The report begins with a Stem Cell Therapy industry definition and scope that lists product definitions, product types, growth rates, and market size estimates. Market concentration and maturity are taking place in North America, Europe, the Middle East, Africa, Asia Pacific, South America and other regions. The report is segmented based on three key aspects: Stem Cell Therapy type, wide range of product applications, and region. In addition, these top regions are subdivided as follows to provide a country-level analysis of the above regions.

The following section describes import/export details, SWOT analysis, and Stem Cell Therapy industry conditions. Describes a detailed analysis of competitor profiles. The Competitive Profile section displays Stem Cell Therapy market presentations, product details, market value, prices and gross profit for 2019. This report details the Stem Cell Therapy new product launches, mergers and acquisitions, plans and industry policies.

Market Segmentation:

Market By Type:

Market By Application:

Region segment covered

North Americao U.S.o Canada Europeo U.K.o Germanyo Franceo Rest of Europe Asia Pacifico Chinao Japano Indiao Rest of Asia Pacific Latin Americao Brazilo Argentinao Rest of Latin America Middle East and Africao Saudi Arabiao UAEo Turkeyo Rest of Middle East and Africa

Browse Detailed Description, TOC, Detailed Segment analysis, Table Of Figures, https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#table-of-contents

Link:
Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network - The Bisouv...

Read More...

Stem Cell and PRP Injection for Knee Osteoporosis Pain and Injury Using US Image Guidance – Magazine of Santa Clarita

Wednesday, March 3rd, 2021

Center for Regenerative Medicine & Stem Cell Therapy at Valencia Medical Center is a pioneer in stem cell regenerative medicine in Santa Clarita Valley has been producing PRP and stem cell treatments for cosmetic treatments for cosmetic rejuvenation, hair restoration and chronic knee pain due to arthritis knee meniscus injury, cartilage, ligaments (ACL, MCL), osteoarthritis treatment.Non-surgical regenerative cell-based treatment uses the bodys natural healing ability to repair damaged bones, muscles, cartilage, tendons and ligaments. Knee injuries are painful and often patients are unable to walk. Our treatment protocol always uses products following FDA guidelines.Injections done with ultrasound guided needle recognition capability to ensure safety as well target the area needing treatment. Plasma; Alpha-2-Macroglobulim (A2M) is the new biologic treatment for your arthritic knee (osteoarthritis)When your hips hurt, or your knee is stiff, or your back is throbbing, that means your joint is bone on bone and there is no lubrication to ease movement.Regenerative medicine giving new hope to patients suffering from painful joint injuries such as knee, shoulder and hip with a chance to live a pain free life.Regenerative cell-based ultrasound guided injection now available to treat pain associated with joint injury. There are indications that it reduces the pain and swelling of the joints and helps lubricating and improve movements.Commonly Treated Conditions: Osteoarthritis of the Hips, Knee, and Shoulders Rotator Cuff tears of the Shoulder Meniscus, ACL and PCL tears of the kneeOur stem cell treatment using your own stem cells and with using imaging guidance ensures precise injection of stem cell, it is a highly-specialized practice.Besides treating above injuries we have advance stem cell micro-needling treatment for the following: Cell-based PRP Hair Restoration combining micro-needling with growth factors and hair follicles voluma vitamins plus BLotinyl T1, Biotin, Anti-aging and Kopexil.Dr. Ibrahim is the staff physician at Valencia Medical Center specializing in regenerative medicine, pain management, and rejuvenation. Call for a consultation at 661-222-9117.

See original here:
Stem Cell and PRP Injection for Knee Osteoporosis Pain and Injury Using US Image Guidance - Magazine of Santa Clarita

Read More...

Animal Stem Cell Therapy Market Potential Growth, Share and Demand Analysis of Key Players MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet NY…

Wednesday, March 3rd, 2021

The global Animal Stem Cell Therapy market is expected to surge at a steady CAGR in the coming years, states the latest Report Hive Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Animal Stem Cell Therapy market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Animal Stem Cell Therapy market.

The research report is committed to giving its readers an unbiased point of view of the global Animal Stem Cell Therapy market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

The following Companies as the Key Players in the Global Animal Stem Cell Therapy Market Research Report: Key players

MediVet BiologicVETSTEM BIOPHARMAJ-ARMCelavetMagellan Stem CellsU.S. Stem CellCells Power JapanANIMAL CELL THERAPIESAnimal Care StemCell Therapy SciencesVetCell TherapeuticsAnimacelAratana Therapeutics

Request a Sample of this report at:@https://www.reporthive.com/request_sample/2470743

Segmental AnalysisThe report has classified the global Animal Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Animal Stem Cell Therapy manufacturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Animal Stem Cell Therapy industry.

Animal Stem Cell Therapy market by Types:

DogsHorsesOthers

Animal Stem Cell Therapy market by Applications:

Veterinary HospitalsResearch Organizations

Regional Analysis:Besides segmental breakdown, the report is highly structured into region wise study. The regional analysis comprehensively done by the researchers highlights key regions and their dominating countries accounting for substantial revenue share in the Animal Stem Cell Therapy market. The study helps understanding how the market will fare in the respective region, while also mentioning the emerging regions growing with a significant CAGR. The following are the regions covered in this report.

The scope of the Report: The research report on the global Animal Stem Cell Therapy market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.The report also includes product portfolios and the list of products in the pipeline. It includes a through explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Get Customized PDF template of this report:https://www.reporthive.com/request_customization/2470743

Key questions answered in the report:

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

Read more:
Animal Stem Cell Therapy Market Potential Growth, Share and Demand Analysis of Key Players MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet NY...

Read More...

Musculoskeletal Disorder Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The…

Wednesday, March 3rd, 2021

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Musculoskeletal Disorder Stem Cell Therapy Market report provides in-depth knowledge and insights into the Musculoskeletal Disorder Stem Cell Therapy market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Musculoskeletal Disorder Stem Cell Therapy market that has been further validated and verified by industry experts and professionals. The Musculoskeletal Disorder Stem Cell Therapy market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Musculoskeletal Disorder Stem Cell Therapy market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Musculoskeletal Disorder Stem Cell Therapy industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Musculoskeletal Disorder Stem Cell Therapy Market:

Osiris Therapeutics NuVasive Takeda (TiGenix) Medi-post

Segmentation of Musculoskeletal Disorder Stem Cell Therapy Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Allogeneic Autologous

By the application, this report covers the following segments:

Muscle disease Skeletal disease

Musculoskeletal Disorder Stem Cell Therapy Market Report Scope

Musculoskeletal Disorder Stem Cell Therapy Geographic Market Analysis:

The latest business intelligence report analyzes the Musculoskeletal Disorder Stem Cell Therapy market in terms of market reach and customer base in key geographic market regions. The Musculoskeletal Disorder Stem Cell Therapy market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Musculoskeletal Disorder Stem Cell Therapy market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Musculoskeletal Disorder Stem Cell TherapyMarket Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Musculoskeletal Disorder Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

View original post here:
Musculoskeletal Disorder Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The...

Read More...

Exclusive Insights on Stem Cell Therapy for Multiple Sclerosis Market 2021-2026: Latest Trends, Drivers, Strategies and Competitive Landscape The…

Wednesday, March 3rd, 2021

The report on the Stem Cell Therapy for Multiple Sclerosis market provides a brief overview of the market along with the product definition and market scope. The sections following the introductory chapter provide an in-depth study of the market based on extensive research analysis. Along with the market dynamics, the report also presents a comprehensive analysis of the market covering the supply and demand forces.

The Stem Cell Therapy for Multiple Sclerosis study report additionally provides analysis on the market share for significant stakeholders in their global capacity as transformers of the overall scale. This qualitative and quantitative analysis will contain key product offerings, crucial differentiators, revenue share, market size, market status, and strategies of top leading players. The report will additionally cover key agreements, associations, and global partnerships soon to change the dynamics of the market on a global scale.

Get Exclusive Sample of Report on Stem Cell Therapy for Multiple Sclerosis market is available at https://www.in4research.com/sample-request/52441

Competitive Landscape Covered in Stem Cell Therapy for Multiple Sclerosis Market Report:

The competitive landscape is a critical aspect that every key player needs to be understood. The report highlights the competitive scenario of the Stem Cell Therapy for Multiple Sclerosis market for knowing the competition at the national and global levels. The market experts also gave an overview of all the top players in the Stem Cell Therapy for Multiple Sclerosis market, considering important aspects such as business areas, production, and product portfolio. Additionally, the companies are examined in the report based on key factors such as company size, market share, market growth, revenue, production volume, and profit.

The Stem Cell Therapy for Multiple Sclerosis Market Report Covers Major Players:

Any Questions/Queries or need help? Speak with our analyst https://www.in4research.com/speak-to-analyst/52441

Stem Cell Therapy for Multiple Sclerosis Market Segmentation:

The global market for Stem Cell Therapy for Multiple Sclerosis is set to find a segmentation in the report that would be based on type and application. These segments have a better acceptance of various factors that can be taken into consideration to understand how the market can chart the future path.

Stem Cell Therapy for Multiple Sclerosis Market Breakdown based on Product Type

Stem Cell Therapy for Multiple Sclerosis Market Breakdown based on Application

Stem Cell Therapy for Multiple Sclerosis Consumption Breakdown Data by Region

For more Customization, Connect with us at https://www.in4research.com/customization/52441

Key Highlights of the Table of Contents:

In this study, the years considered to estimate the market size of Stem Cell Therapy for Multiple Sclerosis Market:

Reasons you should buy this report:

To Buy Full Report, Connect with us at: https://www.in4research.com/buy-now/52441

For More Details Contact Us:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

See the original post here:
Exclusive Insights on Stem Cell Therapy for Multiple Sclerosis Market 2021-2026: Latest Trends, Drivers, Strategies and Competitive Landscape The...

Read More...

Stem Cell Therapy Market By Treatment,Application,End Users And Geography Forecast To 2027 The Bisouv Network – The Bisouv Network

Wednesday, March 3rd, 2021

Maximize Market Research has recently added a new research report to its mega database of research studies. The research report, titled Global Stem Cell Therapy Market2019 Industry Research Report, gives an exhaustive analysis of the current market, including an overview, Stem Cell Therapy products segmentation, market restraints and drivers, and major geographical segments.

The Stem Cell Therapy market analysis also encompasses the competitive outlook of the world Stem Cell Therapy market, furnishing the detailed profiles of the major market players. The important insights and recommendations by Stem Cell Therapy industry adepts would definitely guide the players in persuasively establishing their strategies and policies and achieve a competitive edge in the Stem Cell Therapy business.

Additionally, the Stem Cell Therapy market 2019 report diagnosis the competitive layout of the world Stem Cell Therapy market, comprising an outline of the major industry players, followed by their business strategies, policies, financial aspects and current market developments.

Request For View Sample Stem Cell Therapy Market Report Page :https://www.maximizemarketresearch.com/request-sample/522

The report emphasis on the Top Manufacturers in the world Stem Cell Therapy market, with profits, losses, prices, production, and market share for each and every manufacturer, covering:Businesses.

Stem Cell Therapy Market Key Players,Regions and SegmentationKey Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Key Target Audience:

Stem Cell Associations and OrganizationsGovernment Research Boards and OrganizationsResearch and consulting firmsStem Cell Therapy Market InvestorsHealthcare Service Providers (including Hospitals and Diagnostic Centers)Stem Cell Therapeutic Product Manufacturing OrganizationsResearch LabsClinical research organizations (CROs)Stem Cell Therapy Marketing PlayersPharmaceutical Product Manufacturing CompaniesScope of the Stem Cell Therapy Market Report:

Stem Cell Therapy market research report categorizes the Stem Cell Therapy market based on Application, End users, Treatment, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Stem Cell Therapy market with key developments in companies and market trends.Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Available Customization:

With the given market data, Maximize Market Research offers customization of report and scope of the report as per the requirement

Regional Analysis:

Breakdown of the North America stem cell therapy marketBreakdown of the Europe stem cell therapy marketBreakdown of the Asia Pacific stem cell therapy marketBreakdown of the Middle East & Africa stem cell therapy marketBreakdown of the Latin America stem cell therapy market

By Regions, the report captures (we can add the regions/countries as you want):Europe, North America, South America, Asia-Pacific, Middle East, and Africa

Detailed SWOT analysis of these players has also been included in the Stem Cell Therapy market report to determine the threats and opportunities faced by them while operating in the Stem Cell Therapy industry.

Do Inquiry Before Purchasing Market Stem Cell Therapy Report Here :https://www.maximizemarketresearch.com/inquiry-before-buying/522

The Stem Cell Therapy market 2019 industry research study further analyzes the global Stem Cell Therapy industry in terms of revenue and has presented the historical data and forecast figures with the help of tables, charts, and infographics. The Stem Cell Therapy report also provides a comprehensive analysis of the global Stem Cell Therapy market with the help of several analytical tools and helps in determining the growth prospects and opportunities of the Stem Cell Therapy industry. It also helps in understanding the major factors that affect the structure and profitability of the global Stem Cell Therapy industry.

The size and share of the segment along with the forecast statistics have been included in the scope of the Stem Cell Therapy research study. By geography; the global Stem Cell Therapy industry has been divided into North America, China, Europe, Southeast Asia, Japan, India. The capacity, revenue, export, import, cost, price, consumption, and price of each regional segment of the global Stem Cell Therapy market has been provided in the Stem Cell Therapy research report.

Browse Complete Stem Cell Therapy Report details with ToC and List Of Figures Here:

Table of Contents

Browse Full Report with Facts and Figures of Stem Cell Therapy Market Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/#details

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors .

Contact info:

Name: Vikas Godage

Organization: Maximize Market Research .

Email:[emailprotected]

Contact: +919607065656 / +919607195908

Website: http://www.maximizemarketresearch.com

Link:
Stem Cell Therapy Market By Treatment,Application,End Users And Geography Forecast To 2027 The Bisouv Network - The Bisouv Network

Read More...

10 Best Clinics for Stem Cell Therapy in Thailand [2021 …

Sunday, February 14th, 2021

Stem Cell Therapy involves the use of stem cells to treat different diseases. These are non-differentiated cells of a multicellular organism. All the cells in the body are specialized for a specific function but they are the only cells without an assigned function. They can differentiate into any type of cell as and when required by the body and can proliferate rapidly to produce multiple copies of a specific type. Sources of stem cells are embryos and adult body tissues. In the adults, stem cells are present in bone marrow, brain, liver, skin, skeletal muscles, blood and blood vessels. While embryonic stem cells are derived from a blastocyst. Nowadays, the Umbilical cord is being stored under suitable conditions to get stem cells from it if needed. This is useful as chances of transplant rejection are less because stem cells are derived from your own umbilical cord.

Bone Marrow Transplant is the most commonly used method to treat various types of cancers such as lymphoma, multiple myeloma, and leukemia, etc. through stem cells. It is also used to treat brain diseases, cardiovascular diseases and cell deficiencies such as diabetes mellitus. Recently, anti-aging stem cell treatments have gain fame. It is used to restore your youth and beauty.

Read the original post:
10 Best Clinics for Stem Cell Therapy in Thailand [2021 ...

Read More...

Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung…

Sunday, February 14th, 2021

ELK CITY, Idaho, Feb.10, 2021 /PRNewswire/ --Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today acquisition of the JadiCell, cell therapy, for use in the treatment of acute respiratory distress syndrome and other lung pathologies.

"Having worked with the Team at Therapeutic Solutions International for over 4 years, I am glad to place our highly promising and clinically advanced stem cell therapy into this innovative and cutting-edge company," said Dr. Amit Patel, inventor of the JadiCell. "Therapeutic Solutions International is unique in that it is currently running clinical trials in the area of nutraceuticals, as well as developing preclinical and clinical stage immunotherapies. There are numerous synergies to be had with the existing work and expertise in the Company."

"While there is a lot of excitement about various approaches to lung inflammation, there are very few therapies that not only potently block pathological immunity while concurrently induce regeneration of pulmonary tissues," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "To date, by far the most promising regenerative therapy our scientists have worked with for acute respiratory distress syndrome (ARDS) has been the JadiCell. I am honored to work with our team of experts such as Dr. Francesco Marincola and Dr. Santosh Kesari in leading the JadiCell through Phase III and into the hands of patients."

"It is a significant accomplishment to acquire rights to this extremely promising and cost-effective technology that is scalable and functions as a 'cellular drug,'" said Famela Ramos, Vice President of Business Development. "To our knowledge this is the only stem cell therapy for lung pathologies that does not require animal components and can be generated in sufficient quantities to address the multi-billion-dollar market of ARDS."

"Dr. Patel and his team have been strong collaborators with us since our first licensing deal using the JadiCell for Chronic Traumatic Encephalopathy," stated Timothy Dixon, President and CEO of the Company. "Having worked with these cells, we appreciate that to date they are by far the most effective at production of cytokines, stimulation of regeneration, and inhibition of pathological inflammation. We are extremely confident in our ability to take these cells to the finish line in treatment of end stage lung disease."

About Therapeutic Solutions International, Inc.Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

[emailprotected]

SOURCE Therapeutic Solutions International

Home

The rest is here:
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung...

Read More...

Outlook on the Cell Therapy Global Market to 2027 – Opportunity Analysis and Industry Forecasts – Yahoo Finance

Sunday, February 14th, 2021

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027.

Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient's body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.

Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.

Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.

The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

Story continues

The study provides an in-depth analysis of the global cell therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.

Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the key segments of the industry helps in understanding the forms and types of cell therapy used across the globe.

Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Topics Covered:

Chapter 1: Introduction1.1. Report Description1.2. Key Benefits for Stakeholders1.3. Key Market Segments1.4. Research Methodology1.4.1. Secondary Research1.4.2. Primary Research1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary2.1. Key Findings of the Study2.2. Cxo Perspective

Chapter 3: Market Overview3.1. Market Definition and Scope3.2. Key Findings3.2.1. Top Player Positioning3.2.2. Top Investment Pockets3.2.3. Top Winning Strategies3.3. Porter'S Five Forces Analysis3.4. Impact Analysis3.4.1. Drivers3.4.1.1. Technological Advancements in the Field of Cell Therapy3.4.1.2. The Rise in Number of Cell Therapy Clinical Studies3.4.1.3. The Rise in Adoption of Regenerative Medicine3.4.2. Restraint3.4.2.1. Developing Stage and Pricing3.4.3. Opportunity3.4.3.1. High Growth Potential in Emerging Markets3.5. Impact of Covid-19 on Cell Therapy Market

Chapter 4: Cell Therapy Market, by Cell Type4.1. Overview4.1.1. Market Size and Forecast4.2. Stem Cell4.2.1. Key Market Trends and Opportunities4.2.2. Market Size and Forecast, by Region4.2.3. Market Size and Forecast, by Type4.2.3.1. Bone Marrow, Market Size and Forecast4.2.3.2. Blood, Market Size and Forecast4.2.3.3. Umbilical Cord-Derived, Market Size and Forecast4.2.3.4. Adipose-Derived Stem Cell, Market Size and Forecast4.2.3.5. Others (Placenta, and Nonspecific Cells), Market Size and Forecast4.3. Non-Stem Cell4.3.1. Key Market Trends and Opportunities4.3.2. Market Size and Forecast, by Region

Chapter 5: Cell Therapy Market, by Therapy Type5.1. Overview5.1.1. Market Size and Forecast5.2. Autologous5.2.1. Key Market Trends and Opportunities5.2.2. Market Size and Forecast, by Region5.2.3. Market Analysis, by Country5.3. Allogeneic5.3.1. Key Market Trends and Opportunities5.3.2. Market Size and Forecast, by Region5.3.3. Market Analysis, by Country

Chapter 6: Cell Therapy Market, by Therapeutic Area6.1. Overview6.1.1. Market Size and Forecast6.2. Malignancies6.2.1. Market Size and Forecast, by Region6.2.2. Market Analysis, by Country6.3. Musculoskeletal Disorders6.3.1. Market Size and Forecast, by Region6.3.2. Market Analysis, by Country6.4. Autoimmune Disorders6.4.1. Market Size and Forecast, by Region6.4.2. Market Analysis, by Country6.5. Dermatology6.5.1. Market Size and Forecast, by Region6.5.2. Market Analysis, by Country6.6. Others6.6.1. Market Size and Forecast, by Region6.6.2. Market Analysis, by Country

Chapter 7: Cell Therapy Market, by End-user7.1. Overview7.1.1. Market Size and Forecast7.2. Hospitals & Clinics7.2.1. Key Market Trends and Opportunities7.2.2. Market Size and Forecast, by Region7.2.3. Market Analysis, by Country7.3. Academic & Research Institutes7.3.1. Key Market Trends and Opportunities7.3.2. Market Size and Forecast, by Region7.3.3. Market Analysis, by Country

Chapter 8: Cell Therapy Market, by Region8.1. Overview8.2. North America8.3. Europe8.4. Asia-Pacific8.5. LAMEA

Chapter 9: Company Profiles9.1. Allosource9.1.1. Company Overview9.1.2. Company Snapshot9.1.3. Operating Business Segments9.1.4. Product Portfolio9.1.5. Key Strategic Moves and Developments9.2. Cells for Cells9.2.1. Company Overview9.2.2. Company Snapshot9.2.3. Operating Business Segments9.2.4. Product Portfolio9.3. Holostem Terapie Avanzate Srl9.3.1. Company Overview9.3.2. Company Snapshot9.3.3. Operating Business Segments9.3.4. Product Portfolio9.4. Jcr Pharmaceuticals Co. Ltd.9.4.1. Company Overview9.4.2. Company Snapshot9.4.3. Operating Business Segments9.4.4. Product Portfolio9.4.5. Business Performance9.4.6. Key Strategic Moves and Developments9.5. Kolon Tissuegene, Inc.9.5.1. Company Overview9.5.2. Company Snapshot9.5.3. Operating Business Segments9.5.4. Product Portfolio9.5.5. Key Strategic Moves and Developments9.6. Medipost Co. Ltd.9.6.1. Company Overview9.6.2. Company Snapshot9.6.3. Operating Business Segments9.6.4. Product Portfolio9.6.5. Business Performance9.7. Mesoblast Ltd9.7.1. Company Overview9.7.2. Company Snapshot9.7.3. Operating Business Segments9.7.4. Product Portfolio9.7.5. Business Performance9.8. Nuvasive, Inc.9.8.1. Company Overview9.8.2. Company Snapshot9.8.3. Operating Business Segments9.8.4. Product Portfolio9.8.5. Business Performance9.9. Osiris Therapeutics, Inc.9.9.1. Company Overview9.9.2. Company Snapshot9.9.3. Operating Business Segments9.9.4. Product Portfolio9.10. Stemedica Cell Technologies, Inc.9.10.1. Company Overview9.10.2. Company Snapshot9.10.3. Operating Business Segments9.10.4. Product Portfolio

For more information about this report visit https://www.researchandmarkets.com/r/bja7iz

See the rest here:
Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance

Read More...

Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 – The Courier

Sunday, February 14th, 2021

The global stem cell therapy market is expected to witness a CAGR of 10.6% during the forecast period 2019-2024, and is also anticipated to reach USD 214.5 million by 2024. Growing awareness related to the therapeutic potency of stem cells, development of infrastructure related to stem cell banking and processing, development of advanced genome-based cell analysis techniques, and increasing private-public investment for the development of stem cell therapies are driving the growth of the stem cell therapy market.

Get a free copy of sample report: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/request-sample

Supportive regulations to drive the growth of the stem cell therapy market

Supporting regulations across developing countries, increasing prevalence of chronic diseases, technological advancement in healthcare, cellular therapies are the major advancements in transforming healthcare and identification of new stem cell lines are also fueling the growth of the stem cell therapy market.

Diseases such as osteoarthritis, multiple sclerosis, heart failure, hearing loss and cerebral palsy are some of the diseases that could be treated using stem cell therapies. For instance, according to the WHO by 2050, it is estimated 900 million people will have disabling hearing loss. Moreover, 60 percent of childhood hearing loss is due to preventable causes.

Allogenic stem cell therapy market to hold the larger share in the market

There are two types of stem cell therapy, allogeneic and autologous. Of both, allogenic segment account for the larger share and is also predicted to grow at the faster rate in the coming years in the market due to its extensive therapeutic applications, increasing commercialization of allogeneic products, easy production scale-up process, and growing number of clinical trials related to allogeneic therapies.

The stem cell therapy market has been segmented by therapeutic application into gastrointestinal diseases, musculoskeletal disorders, surgeries, cardiovascular diseases, and wound and injuries. Musculoskeletal disorders category contributed the largest revenue in the market due to increasing prevalence of musculoskeletal disorders and bone & joint diseases, increasing availability of stem cell-based products for the treatment of musculoskeletal disorders, and growing patient preference for effective & early treatment strategies.

Do you have any specific research requirement? Ask for customization: https://www.vynzresearch.com/healthcare/stem-cell-therapy-market/customize-report

The global stem cell therapy market has also been segmented by cell source into adipose tissue-derived mesenchymal stem cell, cord blood cells and bone marrow-derived mesenchymal stem cells. Of all the categories, the bone marrow-derived mesenchymal stem cells are increasingly being used for therapeutic applications.

North America offers huge opportunities for stem cell therapy industry players

The North American stem cell therapy market will remain the largest during the forecast period. The region is further predicted to observe the fastest growth during the forecast period in the global market owing to technological upgradation and large capital invested in the research and development activities. Moreover, increasing number of clinical trials to evaluate therapeutic potential of products, increasing prevalence of chronic diseases, the growing patient base for target diseases, growing public awareness related to the therapeutic potency of therapy, and increasing public-private funding & research grants for developing safe and effective stem cell therapy products are also supporting the growth of the North American stem cell therapy market.

Investing in research and development is the key strategy adopted by the market players

Major players in the industry are investing in the development of innovative and new products, which is strengthening their position in the stem cell therapy market. In February 2018, MEDIPOST announced that FDA has approved its stem cell-based Alzheimers disease drug, NEUROSTEM for clinical trials. Similarly, in March 2017, Osiris Therapeutics launched Prestige Lyotechnology, a method for storage of living cells and tissues.

Some of the key players operating in the stem cell therapy industry are Osiris Therapeutics, Inc., RTI Surgical, Inc., MEDIPOST Co., Ltd., Nuvasive, Inc., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Anterogen Co., Ltd., and Allosource.

More from VynZ Research

Global Stem Cell Banking Market Analysis and Forecast to 2024

The global stem cell banking market is growing at a CAGR of 9.1% during the forecast period reaching USD 10.5 billion by 2024, due to the development of novel technologies of storage, preservation and processing. Stem cell banking is the method of accumulating cord blood, extorting and cryogenically freezing its stem cells for forthcoming use. Cord blood stem cells are used for treating blood diseases such as sickle cell disease, leukemia, and thalassemia. The global stem cell banking market is growing at a significant rate due to the development of novel technologies of storage, preservation and processing. The market has witnessed a high demand for placenta stem cells over the last few years, due to the increasing public awareness regarding the therapeutic prospective of stem cells.

Explore more at: https://www.vynzresearch.com/healthcare/stem-cell-banking-market/request-sample

Global Protein Expression Market Analysis and Forecast to 2024

The global protein expression market was evaluated at USD 1,873.1 million in 2018. The protocol for expression of proteins makes use of expression vectors, competent cells, reagents, instrument, and services. The reagents are the estimated to hold the largest share due to large volume used in the bio-experiments. The significant growth in the protein expression industry is primarily due to the increasing funds from government and non-government organization for protein research, the soaring prevalence of chronic diseases, rising life science industry.

Explore more at: https://www.vynzresearch.com/healthcare/protein-expression-market/request-sample

U.S. Protein Expression Market Analysis and Forecast to 2024

The U.S. protein expression market is expected to grow at a CAGR of 11.6% during the forecast period with its market size predicted to reach USD 1.2 billion by 2024. The U.S. protein expression market is primarily driven by the factors such as the increasing prevalence of chronic diseases, increasing investment for recombinant protein expression, advancement in technology for expression systems, increasing geriatric population, and robust growth of the life sciences industry in the country. Prokaryotic expression systems and mammalian cell expression systems are the major contributors to the protein expression industry in the region.

Explore more at: https://www.vynzresearch.com/healthcare/us-protein-expression-market/request-sample

Contact Us:

VynZ Research

Call: +91-996-028-8381

Toll Free (U.S. and Canada): +1-888-253-3960

Email: enquiry@vynzresearch.com

Connect with Us: LinkedIn | Facebook | Twitter

Go here to see the original:
Global Stem Cell Therapy Market Set to Reach USD 214.5 Million by 2024 - The Courier

Read More...

Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning…

Sunday, February 14th, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021.

Magenta continues to generate encouraging data across our pipeline, furthering our commitment to patients to expand eligibility and improve the clinical outcomes with stem cell transplant, said John Davis Jr., M.D., M.P.H., M.S., Magentas Head of Research & Development and Chief Medical Officer. Our presentations this year at TCT highlight the potential wide-ranging utility of our portfolio, and we are particularly excited to share these results, and to continue our progress in the year ahead.

Oral Presentations Showcasing Clinical Data of MGTA-145 Stem Cell Mobilization Program

Magenta is developing MGTA-145 in combination with plerixafor utilizing complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation. This combination has the potential to be the preferred mobilization regimen for rapid, reliable, predictable and safe collection of high numbers of functional blood stem cells to improve outcomes across autologous and allogeneic stem cell transplantation, which also includes stem cells necessary for all HSC-based gene therapies.

Title: MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)Presenting Author: Chang Li, Ph.D., Division of Medical Genetics, Department of Medicine, University of WashingtonDate and Time of Presentation: Session B Transplantation for Non-Malignant Disease; Monday, February 8, 2021, 3:15PM CST / 4:15PM EST

Data from this preclinical study demonstrate the potential of MGTA-145 plus plerixafor to serve as an efficient, single-dose mobilization regimen for in vivo HSC gene therapy where stem cells could be gene corrected or edited without having to remove them from the body. This could potentially replace current mobilization regimens that rely on ex vivo gene therapy approaches to treat genetic diseases.

Title: MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)Presenting Author: Kevin Goncalves, Ph.D., Magenta TherapeuticsDate and Time of Presentation: Session E Consider the Source: Stem Cell Grafts and Donors; Tuesday, February 9, 2021, 4:00PM CST / 5:00PM EST

Data from this Phase 1 clinical trial with healthy volunteers further underscore the potential utility of MGTA-145 plus plerixafor as an effective, single-day mobilization and collection regimen for autologous and allogeneic HSC transplant. MGTA-145 plus plerixafor mobilized high numbers of HSCs and showed durable engraftment, successful gene-modification and immunosuppressive properties by reducing Graft-versus-Host disease (GvHD) in preclinical models.

Oral Presentation Showcasing Preclinical Study of MGTA-117 Targeted ADC Conditioning Program

Magenta is developing a suite of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magentas targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to transplant or gene therapy, and to reduce or potentially eliminate the need for high dose or high intensity chemotherapy-based treatments. These programs focus on developing targeted products that remove specific cell types, with an approach that is tailored to the patients disease and transplant requirements.

MGTA-117, Magentas most advanced conditioning program, is a CD117-targeted ADC designed to precisely deplete hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant, and to support long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown to be highly selective with potent activity, efficacy and tolerability in preclinical models.

Title: A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)Presenting Author: Leanne Lanieri, M.S., Magenta TherapeuticsDate and Time of Presentation: Session H Novel Conditioning Regimens & Transplantation for Aged Populations, Wednesday, February 10, 2021, 4:00PM CST / 5:00PM EST

Hematopoietic stem cell transplant (HSCT) can often be a curative treatment for patients with acute myeloid leukemia (AML). There is currently a need for safer and more effective targeted conditioning agents, as current conditioning regimens are associated with severe toxicities and high post-transplant relapse or graft failure. MGTA-117 was studied in multiple human leukemic xenograft murine models to mimic untreated and refractory AML. In preclinical models, MGTA-117 significantly increased median survival versus a multi-day standard-of-care regimen using cytarabine. Data from this study demonstrate MGTA-117s potential as a potent, targeted HSCT conditioning agent with anti-leukemic activity, emphasizing its potential to improve HSCT outcomes in AML by reducing the risk of post-transplant relapse.

Poster Presentation Highlighting Preclinical Data of CD45-ADC Targeted Conditioning Program

Magentas other ADC-based conditioning program, CD45-ADC, targets both patient HSCs and disease-causing immune cells. The programs lead target is CD45, a cell surface molecule broadly expressed throughout the hematopoietic and immune systems. CD45-ADC has the potential to significantly increase the number of patients eligible to receive a stem cell transplant, particularly those patients with autoimmune diseases and acute leukemias.

Developing a broad targeting approach for safer patient conditioning prior to HSCT could bring the curative potential of allogeneic HSCT to more patients with both malignant and non-malignant disorders. Current conditioning regimens limit accessibility of this procedure due to toxicity.

Title: Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (AML) (Poster #242)Lead Author: Sharon Hyzy, M.S., Magenta Therapeutics

Data from this study showed conditioning with single agent CD45-ADC enabled complete chimerism in a full mismatch allogeneic HSCT model.

Oral Presentation of MGTA-456 Stem Cell Therapy Expansion Program in Patients with Blood Cancer

Magenta is continuing long-term patient follow up to evaluate MGTA-456 in blood cancers through the investigator-initiated Phase 2 trial in blood cancers at the University of Minnesota and will assess best next steps for the program. Magenta previously announced in June 2020 it had discontinued enrollment in the Phase 2 trial of MGTA-456 in patients with inherited metabolic disorders.

Title: MGTA-456, A CD34 Expanded Cord Blood Product, Permits Selection of Better HLA Matched Units and Results in Rapid Hematopoietic Recovery, Uniform Engraftment and Reduced Graft-Versus-Host Disease in Adults with High-Risk Hematologic Malignancies (Oral Abstract, #31)Presenting Author: Heather Stefanski, M.D., Ph.D., Assistant Professor, Department of Pediatrics, University of MinnesotaDate and Time of Oral Presentation: Session E Consider the Source: Stem Cell Grafts and Donors; Tuesday, February 9, 2021, 3:00PM CST / 4:00PM EST

Twenty-two patients were enrolled in the study, with 18 transplanted with MGTA-456. Compared to transplant patients who had undergone the same conditioning, GvHD prophylaxis and supportive care, patients who received MGTA-456 showed faster neutrophil recovery (median of 17 days compared to 23 days) and better platelet recovery (median 36 days compared to 59 days). Additionally, incidence of grade 2-4 acute GvHD was lower (24% compared to 46%), likely because of the ability to find a better matched cord unit.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancer, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magentas future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting clinical data, projections regarding our long-term growth, cash, cash equivalents and marketable securities, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our clinical programs, the timing, progress and success of our collaborations, as well as other statements containing words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions that can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from pre-clinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, assumptions and uncertainties regarding the impact of the continuing COVID-19 pandemic on Magentas business, operations, strategy, goals and anticipated timelines, Magentas ongoing and planned pre-clinical activities, Magentas ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magentas timelines for regulatory submissions and Magentas financial position; and other risks concerning Magenta's programs and operations set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Go here to see the original:
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning...

Read More...

Page 11234..1020..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick